Nymox CEO Buys 102,844 Shares
Ticker: NYMXF · Form: 6-K · Filed: Oct 22, 2025 · CIK: 1018735
| Field | Detail |
|---|---|
| Company | Nymox Pharmaceutical CORP (NYMXF) |
| Form Type | 6-K |
| Filed Date | Oct 22, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: insider-buy, ceo-purchase, form-6k
Related Tickers: NYMX
TL;DR
Nymox CEO Paul Averback just bought 102,844 shares. Bullish signal?
AI Summary
Nymox Pharmaceutical Corporation reports that its CEO, Dr. Paul Averback, purchased 102,844 shares of the company's stock on October 20, 2025. This transaction was disclosed in a Form 6-K filing submitted to the SEC on October 22, 2025.
Why It Matters
An insider purchase by the CEO can signal confidence in the company's future prospects, potentially influencing investor sentiment.
Risk Assessment
Risk Level: medium — Insider buying can be a positive signal, but the overall risk depends on the company's financial health and market conditions.
Key Numbers
- 102,844 — Shares Purchased (CEO Dr. Paul Averback's recent stock acquisition)
Key Players & Entities
- Nymox Pharmaceutical Corporation (company) — Filing company
- Dr. Paul Averback (person) — CEO and share purchaser
- 102,844 shares (dollar_amount) — Number of shares purchased by CEO
- October 20, 2025 (date) — Date of share purchase
- October 22, 2025 (date) — Date of filing
FAQ
Who purchased shares of Nymox Pharmaceutical Corporation?
Dr. Paul Averback, the company's CEO, purchased shares.
How many shares did Dr. Paul Averback purchase?
Dr. Paul Averback purchased 102,844 shares.
On what date did the CEO's share purchase occur?
The share purchase occurred on October 20, 2025.
What form was filed with the SEC regarding this transaction?
A Form 6-K was filed with the SEC.
When was the Form 6-K filed?
The Form 6-K was filed on October 22, 2025.
Filing Stats: 161 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2025-10-22 14:20:38
Filing Documents
- nymox_6k.htm (6-K) — 9KB
- 0001640334-25-001862.txt ( ) — 10KB
From the Filing
nymox_6k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October, 2025 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant's name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Nymox Pharmaceutical Corporation (the "Company") reports that its CEO, Dr. Paul Averback, completed the purchase of 102,844 shares on October 20, 2025. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 22, 2025 NYMOX PHARMACEUTICAL CORPORATION By: /s/ Paul Averback Name: Paul Averback Title: President and Chief Executive Officer 3